Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of report (date of earliest event reported): November 26,
2016
INNOVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
9171
Towne Centre Drive, Suite 440, San Diego, CA 92122
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
(858)
964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive
Agreement.
On
November 29, 2016, the Company announced that it had entered into
an exclusive license and distribution agreement with J&H Co.
LTD for the commercialization of Zestra® in South Korea. The
exclusive 10-year agreement includes a minimum of $2 million per
year in sales to the Company for a total of $20 million over the
life of the agreement.
A copy
of the press release regarding the above-described agreement is
attached as Exhibit 99.1 and incorporated by reference into this
Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
Press Release
issued November 29, 2016
SIGNATURE
Pursuant
to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
INNOVUS
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
Date: November 29,
2016
|
By:
|
/s/
ROBERT E. HOFFMAN
|
|
|
|
|
|
|
|
|
|
Executive
Vice President and Chief Financial Officer
|
|